Bioorganic Chemistry (2019)
Update date:2022-08-05
Topics:
Wei, Dengshuai
Fan, Haoru
Zheng, Kun
Qin, Xuemei
Yang, Leifu
Yang, Yajuan
Duan, Ye
Zhang, Qiang
Zeng, Chengchu
Hu, Liming
Both c-Met and VEGFR-2 were important targets for cancer therapies. In order to develop reversible and non-covalent c-Met and VEGFR-2 dual inhibitors, a series of [1,4]dioxino[2,3-f]quinazoline derivatives were designed and synthesized. The enzyme assay demonstrated that most target compounds had inhibition potency on both c-Met and VEGFR-2 with IC50 values in nanomolar range especially compounds 7m and 7k. Based on further cell proliferation assay in vitro, compound 7k showed significantly anti-tumor activity in vivo on a hepatocellular carcinoma (MHCC97H cells) xenograft mouse model. We docked the compound 7m with c-Met and VEGFR-2 kinases, and interpreted the SAR of these analogues. All results indicated that the target compounds were dual inhibitors of c-Met and VEGFR-2 kinases that held promising potential in cancer therapy.
View MoreShijiazhuang Frontierchem Co., Ltd.
Contact:+86-311-89271196
Address:4-4-202 No.15 Biandian Street,Shijiazhuang
RongCheng K&S Chemical Co.,Ltd
Contact:0631-7336369
Address:rongcheng ,shandong province china
Contact:+1-416-493-6870
Address:Toronto, Canada
Goldwills Pharmaceuticals Co., Ltd.
Contact:0916-2237889 13991621155
Address:North Suburb of Hanzhong city, Shaanxi Province
Liaoyang Xinyou Chemical Products Co.,Ltd.
Contact:+86-419-5165433 13604191870
Address:Huishang Road6-1, Hongwei District, Liaoyang, Liaoning, China
Doi:10.1021/bc300091d
(2012)Doi:10.1021/ja00024a040
(1991)Doi:10.1055/s-0031-1289700
(2012)Doi:10.1002/ejic.201101369
(2012)Doi:10.1002/ejoc.201101567
(2012)Doi:10.1007/s11172-013-0182-2
(2013)